Indian Pharma Market sees significant revival in March 2021, registers 10.3 percent growth: AIOCD-AWACS Report
New Delhi: The Indian Pharmaceutical Market (IPM) has witnessed a significant revival with a rise of 10.3 per cent for the month of March 2021, compared to 1.1 per cent for the month of February 2021, according to data from market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS)The AIOCD AWACS report also revealed that the March 2020 lockdown, which resulted...
New Delhi: The Indian Pharmaceutical Market (IPM) has witnessed a significant revival with a rise of 10.3 per cent for the month of March 2021, compared to 1.1 per cent for the month of February 2021, according to data from market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS)
The AIOCD AWACS report also revealed that the March 2020 lockdown, which resulted in relatively higher growth for the Cardio-Diabetes segment on March 20 and a dip in other therapy fields, has now normalised in mid-March 21 data. This is the reason why month March 21 growth for the Cardio-Diabetes segment is on the lower side and many other therapy areas are on the higher side.
A detailed analysis showed that Cardiac registered a monthly growth of 6.3% in March 2021, compared to 7.3% in February 2021. Anti-diabetic sales increased by only 0.3 per cent in March 2021, compared to 4.3 per cent in February 2021.
Anti-invectives, which had been growing at a negative rate of 11.3 per cent since the post-lockdown period, grew at an 8.5 per cent rate in March 2021.
The report further included that gastrointestinal drugs that grew at a faster rate of 21.6 per cent in March 2021 compared to 9.9 per cent in February 2021. Vitamins/minerals/nutrients, meanwhile, grew at a faster pace of 22.2 per cent in March 2021 compared to 8.6 per cent in February 2021.
Furthermore, pain/analgesics, neuro/CNS drugs, gynecological, antineoplastic hormones, and opthal/otologicals grew at 14.6%, 9.6%, 22.5%, 10.9%, and 13.1%, respectively.
The respiratory segment is still on a slow recovery path with a growth rate of-15.1% in March 2021 compared to-20.3% in February 2021.
According to the study, Cipla topped the list of 100 corporate with an 8.1% growth rate in March 21 without the Bonus unit, followed by Zydus Cadila with a 5.1% growth rate, Torrent with a 4.1% growth rate, and Intas with a 4% growth rate in March 21.
